(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 March 2023 (16.03.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/037268 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2022/058428

(22) International Filing Date:
07 September 2022 (07.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/241,914	08 September 2021 (08.09.2021)	US
63/293,591	23 December 2021 (23.12.2021)	US
63/351,639	13 June 2022 (13.06.2022)	US
63/374,282	01 September 2022 (01.09.2022)	US

(71) Applicant: **ORUM THERAPEUTICS, INC.** [KR/KR]; 2F, 281-25, Munji-ro, Yuseong-gu, Daejeon 34050 (KR).

(72) Inventors: **FISHKIN, Nathan**; Orum Therapeutics, Ipsen Innovation Center/Biolabs, 650 East Kendall St., Cambridge, Massachusetts 02142 (US). **BAI, Chen**; Orum Therapeutics, Ipsen Innovation Center/Biolabs, 650 East Kendall St., Cambridge, Massachusetts 02142 (US). **TAKROURI, Khuloud**; Orum Therapeutics, Ipsen Innovation Center/Biolabs, 650 East Kendall St., Cambridge, Massachusetts 02142 (US). **PARK, Peter U.**; Orum Therapeutics, Ipsen Innovation Center/Biolabs, 650 East Kendall St., Cambridge, Massachusetts 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES

(57) Abstract: The present disclosure provides traceless linkers, which can link an inducer of protein-protein interaction to a cell binding agent. Also provided are compositions comprising the linked compounds. The compounds and compositions are useful for treating diseases such as cancer in subjects in need thereof.

WO 2023/037268 A1